TransCon PTH Nears US Approval for Hypoparathyroidism : vima

Ascendis is working to address the FDA's manufacturing concern and awaits a European regulatory decision.

Related Keywords

Silver Spring , Maryland , United States , New York , Columbia University , American , Mishaelar Rubin , Thanh Hoang , Ascendis Pharma , Company Addressing , European Union , Department Of Medicine , Walter Reed National Military Medical Center , Drug Administration , Division Of Endocrinology , American Association Of Clinical Endocrinology , American Association , Clinical Endocrinology , Annual Meeting , Medscape Medical , Metabolic Bone Disease , Medscape Medical News , Bone Turnover Improved , Presented May , Thyroid Disorder , Hormone Replacement Therapy , Ostmenopausal Hormone Replacement Therapy , Art , Calcium , Hypoparathyroidism , Vitamins , Bones , Metabolic Bone Disorder , Isorders Of Bone Mineralization , Endocrinology , Ndocrine System , Europe , European , Dietary Supplements , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Hypercalcemia , Hypocalcemia , Par ,